Plant Summary

  Plant Information

TCMBank_ID:

TCMBANKHE004577

ID:

TCMBANKHE004577

植物拉丁名:

pericarpium papaveris
显示图片

功能与主治:

1. Astringe the intestine, relieve diarrhea and alleviate pain. 2. Astringe the lung and relieve cough./Enduring cough, chronic diarrhea, prolapse of rectum, pain in stomach duct and abdomen.

药用植物名:

罂粟壳

药用部位:

capsule

药味:

Mild; Sour; Punkery

经络:

Lung; Large Intestine; Kidney

临床特征:

1. Slowing the rate of breathing and depressing the cough reflex, and exerting an antitussive effect. 2. Relaxing the smo9th muscles of gastrointestinal tract and trachea. 3. Being an analgesic acting on the central nervous system

治疗类型:

收涩药

TCM_ID_id:

6842

SymMap_id:

463

TCMSP_id:

810

   植物对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN000361 norcotine
TCMBANKIN001990 Norswertianin norswertianin; 9H-Xanthen-9-one, 1,2,6,8-tetrahydroxy-; 1,3,7,8-Tetrahydroxyxanthone; 1,2,6,8-Tetrahydroxy-xanthen-9-one; CHEBI:7637; AC1NQYTY; 1,2,6,8-Tetrahydroxy-9H-xanthen-9-one; CHEMBL187043; 9H-Xanthen-9-one, 1,2,6,8-tetrahydroxy- (9CI); Xanthen-9-one, 1,2,6,8-tetrahydroxy-; Norswetianin; 1,2,6,8-Tetrahydroxyxanthone; 5-18-05-00185 (Beilstein Handbook Reference); CTK4E8821; BDBM50155434; AK594687; 1,2,6,8-tetrahydroxyxanthen-9-one; AKOS030562783; C10088; 22172-15-2; DTXSID90176708; LS-162505; 1,2,6,8-tetrahydroxy-9-xanthenone; BRN 0270047; 9H-Xanthen-9-one,1,2,6,8-tetrahydroxy- C13H8O6 260.2 C1=CC2=C(C(=C1O)O)C(=O)C3=C(C=C(C=C3O2)O)O
TCMBANKIN003894 (-)-thebaine C19H21NO3 311.4 g/mol CN1CCC23C4C(=CC=C2C1CC5=C3C(=C(C=C5)OC)O4)OC
TCMBANKIN008254 Oxysanguinarine Hydroxysanguinarine; 548-30-1; CHEBI:31679; AC1L9F22; C12222; oxysanguinarine; DTXSID80203274; (1,3)Benzodioxolo(5,6-c)-1,3-dioxolo(4,5-i)phenanthridin-14(13H)-one, 13-methyl-; dicyanide C20H13NO5 347.32 CN1C2=C(C=CC3=CC4=C(C=C32)OCO4)C5=C(C1=O)C6=C(C=C5)OCO6
TCMBANKIN013157 thebaine C19H21NO3 311.4 g/mol CN1CCC23C4C(=CC=C2C1CC5=C3C(=C(C=C5)OC)O4)OC
TCMBANKIN014279 Papaverrubine B papaverrubine b C21H23NO6 385.4 g/mol COC1C2=C(C=CC3=C2OCO3)C4C(O1)C5=CC(=C(C=C5CCN4)OC)OC
TCMBANKIN016040 Palaudine 5-[(6,7-dimethoxyisoquinolin-1-yl)methyl]-2-methoxy-phenol; 5-[(6,7-dimethoxyisoquinolin-1-yl)methyl]-2-methoxyphenol; Phenol, 5-((6,7-dimethoxy-1-isoquinolinyl)methyl)-2-methoxy-; 5-[(6,7-dimethoxy-1-isoquinolyl)methyl]-2-methoxy-phenol; 18694-10-5; 3'-Hydroxypapaverine; 5-[(6,7-dimethoxy-1-isoquinolyl)methyl]-2-methoxyphenol; palaudine C19H19NO4 325.36 COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)O
TCMBANKIN017993 vitamin c D01CWN; Cell C; Ronotec 100; P 1110; Suncoat VC 40; D-threo-hex-2-enoic acid gamma-lactone; Citrovit; 2-o-(beta-d-glucopyranosyl)-ascorbic acid_qt; Juvamine; SCHEMBL13468284; Vasc; CHEBI:51384; D-Lyxoascorbic acid; CHEMBL1253320; AK481251; Chewcee; D-xyloascorbic acid; C8DQ5M1Y1E; MLS001066386; AK322241; Ascorbic acid, D-; AC1LD8K5; E 300; Scorbu C; 10504-35-5; Ascorbicacid; l(+)-ascorbic acid; ZINC100006137; L-ascorbate (vitamin C); (5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; (+)-Ascorbic acid; UNII-C8DQ5M1Y1E; Ascorbinsaure; Ceklin; VC 97; (2S)-2-[(1R)-1,2-bis(oxidanyl)ethyl]-4,5-bis(oxidanyl)furan-3-one; Vicin; L-ascorbate acid; L-ascorbic acid; L-dehydroascorbic acid; ascorbate; D-threo-hex-2-enono-1,4-lactone; Kangbingfeng; D-Ascorbic acid; Viscorin 100M; ZINC100028197; (2S)-2-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroxy-3-furanone; L-Ascorbic acid (8CI,9CI); Proscorbin Redoxon Ribena Ronotec 100; Hex-2-enonic acid gamma-lactone, L-threo; (5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxy-2,5-dihydrofuran-2-one; Ascorbic acid; DL-Ascorbic acid; AKOS000278050; Cebion, gamma-lactone; F91F7DA3-A3D5-4FB4-A6E7-C497C48D192A; GTPL4651; SMR000471843; Xyloascorbic acid, L-; Rontex 100; Rovimix C; (2S)-2-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one; A828310 C6H8O6 176.12 C(C(C1C(=C(C(=O)O1)O)O)O)O
TCMBANKIN019205 Cryptogenin Cryptogenine; 3-beta,26-Dihydroxycholest-5-ene-12,22-dione; cryptogenin; Cholest-5-ene-16,22-dione, 3beta,26-dihydroxy-, (20S,25R)- (8CI); Cryptogenine [French]; 3-beta,26-Dihydroxycholest-5-ene-12,22-dione [French]; BXC9X8B37J; 3beta,26-Dihydroxycholest-5-ene-16,22-dione; UNII-BXC9X8B37J; NSC 93751; Cholest-5-ene-16,22-dione, 3-beta,26-dihydroxy-, (20S,25R)- (8CI); Cholest-5-ene-16,22-dione, 3,26-dihydroxy-, (3-beta,25R)-; (3-beta,25R)-3,26-Dihydroxycholest-5-ene-16,22-dione C27H42O4 430.62 [H+].CC(CCC(=O)C(C)C1C(=O)CC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)CO
TCMBANKIN020119 Dihydrosanguinarine AIDS-106789; Dihydro Sanguinarine; ZINC895645; HY-N0902; 3586AH; ZB015056; Hydrosanguinarine; AIDS106789; dihydroavicine; CC-26826; UNII-3H1ZKG80F7; C20H15NO4; MolPort-039-139-629; AKOS030526138; AK546683; CHEMBL465678; FT-0667147; C05191; 3606-45-9; 13,14-Dihydro-13-methyl-[1,3]benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridine; AC1Q6ZQL; 3arv; 24-METHYL-5,7,18,20-TETRAOXA-24-AZAHEXACYCLO[11.11.0.0(2),(1)?.0?,?.0(1)?,(2)(2).0(1)?,(2)(1)]TETRACOSA-1,3,8,10,12,14(22),15,17(21)-OCTAENE; CS-3819; dihydrosanguinarine; 13, 14-dihydro-13-methyl-[1, 3]benzodioxolo[5, 6-c]-1, 3-dioxolo[4, 5-i]phenanthridine; 13,14-Dihydrosanguinarine; SCHEMBL420383; C-23832; Ambap3606-45-9; 13-methyl-13,14-dihydro-2H,10H-[1,3]dioxolo[4,5-i][1,3]dioxolo[4',5':4,5]benzo[1,2-c]phenanthridine; DTXSID00189627; 3lle; 3as0; 3H1ZKG80F7; CHEBI:17209; (1,3)Benzodioxolo(5,6-c)-1,3-dioxolo(4,5-i)phenanthridine, 13,14-dihydro-13-methyl-; AC1L3XTP C20H15NO4 333.34 CN1CC2=C(C=CC3=C2OCO3)C4=C1C5=CC6=C(C=C5C=C4)OCO6
TCMBANKIN020725 beta-narcotine AKOS003673314; IDI1_000323; CHEBI:95149; SCHEMBL14386820; β-narcotine; AC1L2EQH; MolPort-006-822-780; 6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one; KBio1_000323; DivK1c_000323; CTK8G2016; NINDS_000323; LS-84359; 1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (R-(R*,R*))- C22H23NO7 413.4 g/mol CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3
TCMBANKIN020949 papaverine Cepaverin; AOB5339; 58-74-2; MFCD00012745; ZINC00056555; NCI60_003183; Drapavel; DSSTox_RID_77939; NCI-C56359; Myobid; BB_NC-0726; H754; Isoquinoline, 6,7-dimethoxy-1-veratryl-, hydrochloride; Papaverine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material; Dynovas; Artegodan; Papavarine chlorhydrate; DTXSID9025825; NCGC00094258-03; Isoquinoline,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, hydrochloride; 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; Alapav; Papacon; AIDS000185; NSC35443 (HCL); SMR000058283; KBioGR_000914; Spasmo-Nit; Papavarine hydrochloride; HMS1569F08; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-isoquinoline; DSSTox_CID_5825; Papaverine hydrochloride (JP17/USP); Pameion; NCGC00094258-06; BSPBio_002153; Chlorhydrate de papaverine [French]; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-, hydrochloride (1:1); SBB080541; AIDS-000185; Oprea1_387689; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; I01-13837; Optenyl; CTK8G2272; Papaverine Hcl; WLN: T66 CNJ B1R CO1 DO1& HO1 IO1; Dispamil; Lopac0_000957; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-; Isoquinoline,7-dimethoxy-1-veratryl-, hydrochloride; MLS000028497; KBio2_005607; Lapav; Ro-Papav; Papanerin-HCl [German]; Cardiospan; Tox21_110226_1; TNP00305; Pavnell; HMS1920F06; LP00957; Pavagrant; SR-01000003098-2; SDCCGMLS-0003037.P003; AC1L1LRO; 6,7,3',4'-Tetramethoxy-1-benzylisoquinoline hydrochloride; 6,7-Dimethoxy-1-veratrylisoquinoline; Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); TR-031684; Pavacot; Papaverine hydrochloride, United States Pharmacopeia (USP) Reference Standard; Paveron; Spectrum4_000467; Spectrum_000071; LS-267; SR-01000003098-11; Forpavin; Durapav; Cardoverina; Prestwick2_000583; Papaverine hydrochloride, powder; CCRIS 3804; 5-21-06-00182 (Beilstein Handbook Reference); Paverolan; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline hydrochloride; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline; FT-0631269; ACon1_002094; NCGC00094258-04; EINECS 200-397-2; Papaverine; AC1Q3DLI; CHEMBL98123; Pavadel; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline hydrochloride; 58-74-2 (Parent); InChI=1/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H; REGID_for_CID_6084; BBC/116; Dipav; NCGC00094258-01; P0016; SPBio_002645; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 6,7-Dimethoxy-1-veratrylisoquinoline hydrochloride; NCGC00261642-01; PubChem6305; Cerebid; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; Oprea1_810508; Vasal; Papanerin; P 3510; 23473EC6BQ; Pharmakon1600-01500459; C06533; Lopac-P-3510; Vaso-Pav; SCHEMBL121268; DivK1c_000321; Papaverina [Italian]; NSC136630; NSC 136630; KBio2_000471; Spectrum3_000537; MLS002222208; component of Copavin; 58-74-2 (FREE BASE ); Therapav; BG00717685; Prestwick1_000583; Pavacen; Copavin; AK-67336; Dilaves; PAP H; 4-[(6,7-dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene, chloride; UNII-23473EC6BQ; NCGC00015810-01; Papaversan; Tox21_500957; DSSTox_GSID_25825; Papaverine chlorohydrate; Papaverine hydrochloride [USAN:JAN]; EINECS 200-502-1; EU-0100957; Robaxapap; NCGC00094258-02; Papaverine hydrochloride [USP:JAN]; Papaverine, hydrochloride; Papaverine (hydrochloride); PAPAVERINE HYDROCHLORIDE; Prestwick0_000583; MEGxp0_001880; Delapav; D02218; Pavacap; BPBio1_000470; Ceraspan; AS-13262; NCGC00015810-03; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-, hydrochloride; Papanerin-hcl; NCGC00015810-12; KB-146860; RS 47; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline;hydrochloride; CAS-61-25-6; UOTMYNBWXDUBNX-UHFFFAOYSA-N; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, hydrochloride (1:1); Papaverin; ACon1_000238; KBio2_003039; Prestwick3_000583; Pavabid (TN); Papaverine monohydrochloride; WLN: T66 CNJ B1R CO1 DO1& HO1 IO1 &GH; NSC757256; Pavatest; Papaverinium chloride; SR-01000003098; ST077145; ST023301; Pavakey; NSC-35443; BRN 0312930; Isoquinoline, 6,7-dimethoxy-1-veratryl- (8CI); SR-01000003098-9; 61-25-6 (HCL); SPBio_001015; NSC35443; MLS001148655; BSPBio_000426; IDI1_000321; Spectrum2_000978; Pavased; SPECTRUM1500459; Papanerine; NSC-757256; NCGC00094258-05; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)-isoquinoline hydrochloride; KBioSS_000471; HY-18077A; Papaverine hydrochloride, European Pharmacopoeia (EP) Reference Standard; BG01663857; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinolinehydrochloride; S-M-R; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; NINDS_000321; Papalease; Papaverine hydrochlorid; KBio3_001653; Pap-Kaps-150; MolPort-000-847-203; NCGC00015810-02; Isoquinoline, 6,7-dimethoxy-1-veratryl-; API0003748; CCG-40065; CS-5015; BAS 00674058; ARONIS23834; AKOS005111070; 61-25-6; NSC 35443; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; C20H22ClNO4; 1-(3,7-dimethoxyisoquinoline hydrochloride; Isoquinoline, 6,7-dimethoxy-1-veratryl-, hydrochloride (8CI); Tox21_110226; 6,3',4'-Tetramethoxy-1-benzylisoquinoline hydrochloride; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-isoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; Spectrum5_001188; Opera_ID_1617; Prestwick_376; SR-01000003098-4; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-; KBio1_000321 C20H21NO4 339.39 COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC
TCMBANKIN021392 zingiberene CHEMBL479020; 495-60-3; 1,3-Cyclohexadiene, 5-(1,5-dimethyl-4-hexenyl)-2-methyl-, (S-(R*,S*))-; (5R)-5-[(1S)-1,5-dimethylhex-4-enyl]-2-methylcyclohexa-1,3-diene; (5S)-5-[(1R)-1,5-dimethyl-4-hexenyl]-2-methyl-1,3-cyclohexadiene; (5R)-5-[(1S)-1,5-dimethylhex-4-enyl]-2-methyl-cyclohexa-1,3-diene; (S-(R*,S*))-5-(1,5-Dimethylhexen-4-yl)-2-methyl-1,3-cyclohexa-1,3-diene; AKOS015968402; Zingiberene; (5S)-2-Methyl-5-[(1R)-1,5-dimethyl-4-hexenyl]-1,3-cyclohexadiene; alpha-Zingiberene; [S-(R*,S*)]-5-(1,5-dimethylhexen-4-yl)-2-methyl-1,3-cyclohexa-1,3-diene; EINECS 207-804-2; LMPR01030039; ent-Zingiberene; ZINC44431718; (5R)-2-methyl-5-[(2S)-6-methylhept-5-en-2-yl]cyclohexa-1,3-diene; C09750; (5S)-2-methyl-5-[(2R)-6-methylhept-5-en-2-yl]cyclohexa-1,3-diene; CHEBI:583099; (+)-zingiberene C15H24 204.35 g/mol CC1=CCC(C=C1)C(C)CCC=C(C)C
TCMBANKIN021670 Thellungianin F [4-[(Z)-prop-1-enyl]phenyl] 2-methylbutanoate; AC1NT0ZM; thellungianin f 218.32 CCC(C)C(=O)OC1=CC=C(C=C1)C=CC
TCMBANKIN025420 codeine Morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-; HSDB 3043; O(3)-methylmorphine; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-; 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol; C06174; l-Codeine; CCRIS 7555; Morphine monomethyl ether; C1653_SIGMA; Methylmorphine; Codeine; CHEBI:16714; 3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6alpha-ol; (5alpha,6alpha)-17-methyl-3-(methyloxy)-7,8-didehydro-4,5-epoxymorphinan-6-ol; Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8CI); Coducept; Norcodeine, N-methyl; 76-57-3; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5-alpha,6-alpha)- (9CI); Codicept; Morphine-3-methyl ester; Codeine anhydrous; O3-Methylmorphine; EINECS 200-969-1; Morphine 3-methyl ether; Norcodine, N-methyl; Codein; Morphine-3-methyl ether; STOCK1N-42851; (-)-Codeine; Codeine solution; BB_NC-0138; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9CI); 7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol; C5901_SIGMA; Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- C18H21NO3 299.36 CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O
TCMBANKIN028288 morphine (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol; 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol; RMS; Hard stuff; Morpho; Cube juice; 47106-99-0; EINECS 200-320-2; 64-31-3 (SULFATE); (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphin; Nepenthe; Roxanol; (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL; CCRIS 5762; AIDS-001987; Moscontin; Statex SR; Unkie; Morphia; Morphina [Italian]; M-Eslon; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-; Morphinum; Ms Emma; 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Dolcontin; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-; Morphinism; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)-; MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE; 57-27-2 (FREE BASE ); (-)-Morphine; Dulcontin; 8053-16-5; Meconium; (-)Morphine sulfate; Ospalivina; NSC11441(SULFATE); Morphium; Morphin [German]; l-Morphine; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl-; Dreamer; HSDB 2134; Hocus; 85201-37-2; AIDS001987; 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol; DEA No. 9300; Duromorph; Morfina [Italian]; Morphina; Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-; MOI; CHEBI:17303 C17H19NO3 285.34 CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
TCMBANKIN030321 Dihydrosecurinine dihydrosecurinine 219.31 C1CCN2C(C1)C34CC2CC=C3CC(=O)O4
TCMBANKIN032077 Erythroculine erythroculine; AC1NSV8C; methyl 2,11-dimethoxy-2,3,5,6,8,9-hexahydro-1H-indolo[7a,1-a]isoquinoline-12-carboxylate C20H25NO4 343.42 COC1CC=C2CCN3C2(C1)C4=C(CC3)C=C(C(=C4)C(=O)OC)OC
TCMBANKIN032683 norsanguinarine (1,3)Benzodioxolo(5,6-c)-1,3-dioxolo(4,5-i)phenanthridine; Sanguinarine, 13-demethyl-; 522-30-5; 5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.0;{2,10}.0;{4,8}.0;{14,22}.0;{17,21}]tetracosa-1(13),2,4(8),9,11,14,16,21,23-nonaene; NSC-143762; NSC 143762; 13-Demethyl-Sanguinarine; AKOS030535106; [1,3]Benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridine; 7,8-Bis(methylenedioxy)benzo[c]phenanthridine; 5157-23-3; AC1L3Z0I; AK560647; MolPort-039-338-524; 1,3-Dioxolo[i][1,3]dioxolo[4,5]benzo[1,2-c]phenanthridine; SCHEMBL16125304; ZINC1727527; [1,6-c]-1,3-dioxolo[4,5-i]phenanthridine; [1,3]Dioxolo[4',5':4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridine; NSC143762; 1,3-Dioxolo(i)(1,3)dioxolo(4,5)benzo(1,2-c)phenanthridine; 1,3]dioxolo[4,5]benzo[1,2-c]phenanthridine; AC1Q4WKG; CNXVDVMAYXLWPD-UHFFFAOYSA-N; Norsanguinarine C19H11NO4 317.29 C1OC2=C(O1)C3=CN=C4C(=C3C=C2)C=CC5=CC6=C(C=C54)OCO6
TCMBANKIN034931 Narcotoline 3-(4-hydroxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6,7-dimethoxy-3H-2-benzofuran-1-one; 6-Methyl-4-hydroxy-5,6,7,8-tetrahydro-5-(3-oxo-4,5-dimethoxy-1,3-dihydroisobenzofuran-1-yl)-1,3-dioxolo[4,5-g]isoquinoline; AC1MRPAC; narcotoline C21H21NO7 399.39 CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)O)OCO3
TCMBANKIN038566 Sedoheptulose Sedoheptulose anhydride monohydrate; MFCD00150523; 2,7-Anhydro-; CTK8G3083; AKOS024319163; SEDOHEPTULOSAN HYDRATE; B7D9656A-970A-4034-801E-AA7465E3007F; SEDOHEPTULOSAN MONOHYDRATE; A-D-altro-heptulopyranose 210.18 g/mol
TCMBANKIN049422 oxysophocarpine OXYSOPHOCARPINE C15H22N2O2 262.35 g/mol C1CC2CN3C(CC=CC3=O)C4C2[N+](C1)(CCC4)[O-]
TCMBANKIN057935 D-sedoheptulose (3S,4R,5R,6R)-1,3,4,5,6,7-hexahydroxyheptan-2-one; CHEBI:16802; D-Altro-2-heptulose; D-altro-hept-2-ulose;l-galactoheptulose;d-mannoheptulose;Sedoheptulose; (3S,4R,5R,6R)-1,3,4,5,6,7-hexahydroxyheptan-2-one; D-Sedoheptulose, >=95% (TLC); ZINC8579422; altro-Heptulose; 40A0W1XJ6X; UNII-40A0W1XJ6X; AC1NUSHL; SCHEMBL119427; CHEBI:16802; D-altro-hept-2-ulose; D-Altro-2-heptulose; 3019-74-7;L-Galactoheptulos; D-Sedoheptulose, >=95% (TLC); ZINC8579422; altro-Heptulose; 40A0W1XJ6X; UNII-40A0W1XJ6X; D-Mannoheptulose; AC1NUSHL; SCHEMBL119427; CHEBI:16802; D-altro-hept-2-ulose; D-Altro-2-heptulose; 3019-74-7 C7H14O7 210.18 g/mol C(C(C(C(C(C(=O)CO)O)O)O)O)O
TCMBANKIN058003 sanguinarine Sanguinarine, 8CI); NSC-59270; sanguinarine ; NSC-35607; [1,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl-, nitrate,sanguiritrin C20H14NO4+ 332.3 g/mol C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6
TCMBANKIN058057 D-Chiro-Inositol Chiro-inositol;mesoinositol; Myo-inositol; i-inositol; Inositol-c; scyllo-insitol; Inositol;KS-00001292; TR-022051; BG01505581; MFCD01321249; CTK1C5947; AKOS024318869; INOSITOL (D); Inositene; CHEBI:27374; D-(+)-chiro-Inositol; LT03328768; I-6500; 2H3; (1R,2R,3R,4S,5S,6s)-cyclohexane-1,2,3,4,5,6-hexaol; D07CPO; W-203081; NCGC00178580-01; ZINC103574430; Myoinositol; ZINC100019018; NSC-103959; SCHEMBL13114116; UNII-1VS4X81277; 12513-EP2292610A1; AKOS015912934; NSC25142; Inosite; (1R,2R,3R,4R,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; BG00909558; 1,2,3,4,5,6-Cyclohexanehexol, (cis,cis,cis,trans,cis,trans)- #; BG01505582; NSC-127230; AK307531; Inositol, cis-; NSC 8101; 643-12-9; CHEBI:23311; MolPort-001-785-905; NSC-404118; KB-296111; 12513-EP2316831A1; K572; MolPort-003-719-862; Inositol, chiro-; Inositol (VAN8C; Isoinositol; I14-47230; GTPL4645; s4530; EINECS 211-394-0; 1,2,3,4,5,6-HEXAHYDROXY-CYCLOHEXANE; CHEBI:22357; AK324051; Inositol [USAN:NF]; bmse000922; CDAISMWEOUEBRE-OQYPVSDDSA-N; DSSTox_RID_76890; NCGC00255362-01; 1VS4X81277; 1D-Chiro-inositol; chiro-inositol; BG01505565; 488-55-1; BG01505566; AKOS015960429; NSC103959; 576-63-6; SBI-0051369.P003; 1,2,4,5/3,6-cyclohexanehexol; I14-2742; 12513-EP2277880A1; AKOS015960633; J101.891D; A834712; Scyllitol; CHEBI:23927; KM0846; 1,2,3,4,5,6-Hexahydroxycyclohexane; Spectrum3_001053; HMS2091N13; MLS001332378; MolPort-001-742-552; NCIOpen2_008191; Cocositol; Phaseomannitol; Scyllite; myo-Inositol, 98% 100g; BSPBio_002606; KBio2_002075; FT-0693614; Inositol, United States Pharmacopeia (USP) Reference Standard; TR-017741; CCRIS 6745; STL453612; ZINC253837650; I0631; D03SHD; SCHEMBL6791918; 3635-EP2292088A1; AB00051982_13; CHEBI:17268; TR-022053; Iso-inositol; MFCD00077932; CTK8B3795; myo-Inositol, >=99%; GTPL4495; C19891; KSC225S4P; ZINC100073149; DSSTox_GSID_23146; MLS001335965; TL8004551; SMR000857319; bmse000102; AJ-26654; 887751-76-0; DB03106; UNII-9O6Y5O4P9W; 38876-99-2; myo-Inositol, BioUltra, >=99.5% (HPLC); Inositol, neo-; Matezodambose; 6R79WV4R10; I0040; Mesol; W-203392; NSC404118; 1,2,4/3,5,6-Cyclohexane-1,2,3,4,5,6-hexol; Rat antispectacled eye factor; Inositol FCC; 3635-EP2305682A1; 1,2,3,5/4,6-Cyclohexanehexol; BG01505593; cis-Inositol, >=98.0% (TLC); Tox21_302035; CDAISMWEOUEBRE-LOLGQZEGSA-N; 643-10-7; AKOS027327401; 1,2,4/3,5,6-Hexahydroxycyclohexane; 3635-EP2295417A1; CHEMBL278373; FT-0652045; 3635-EP2305677A1; 1,2,3,4,5,6-Cyclohexanehexol; Neo-inositol; (1s,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Q-201583; Hexahydroxycyclohexane; SCHEMBL187278; (1S,2S,4S)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; CHEMBL1231671; EINECS 207-682-0; I14-47232; 1D-myo-Inositol; CHEMBL468154; SCHEMBL13058696; SC-18136; 3635-EP2280282A1; DB13178; 3635-EP2289886A1; Spectrum_001595; Inositol, Pharmaceutical Secondary Standard; Certified Reference Material; NSC-757076; AKOS006240678; I14-60538; 12513-EP2374790A1; CJ-23964; AK102790; UNII-63GQX5QW03; INS; 87-89-8; Scyllite (for the structural isomer scyllo-Inositol); 2os9; CHEMBL1222251; I14-47231; MLS001335966; (1R,2R,3S,4R,5r,6S)-cyclohexane-1,2,3,4,5,6-hexaol; alloinositol; ANW-43204; 4irx; KS-1420; Inositol (VAN); inositols; 4L6452S749; C06153; (1R,2R,3R,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Inosital; ZINC100037751; AB0014290; MEGxp0_001817; (1r,2R,3S,4r,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; Inositol, myo-; ELND 005; 13719-EP2311831A1; cyclohexane-1,2,3,4,5,6-hexol; FT-0627237; AKOS015912905; KS-0000146H; (+)-Chiro-Inositol; AC1L1A9E; L-(-)-chiro-Inositol, 95%; (1R,2R,3R,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; myo-Inositol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture; 3635-EP2305636A1; C06151; 12513-EP2292597A1; myo-Inositol, purum, >=98.0% (HPLC); Inositol, scyllo-; MFCD00799555; 12513-EP2298768A1; NSC-25142; 1,2,3/4,5,6-cyclohexanehexol; MFCD00799556; cis-1,2,4-trans-3,5,6-Cyclohexanehexol; ST24024704; Inositol, myo- (8CI); SCHEMBL13114115; GTPL4649; Bios I; M01914; ST50406013; NSC127230; FT-0632209; ZINC250615063; AC1Q2AJJ; SR-05000001655; Mesoinosite; Muscle sugar; ZINC102201844; 6917-35-7; myo-Inositol, European Pharmacopoeia (EP) Reference Standard; 3635-EP2308879A1; Insitolum; D-myo-Inositol, Cell Culture Grade; I0630; Spectrum4_001193; epi-Cyclohexanehexol; SCHEMBL187796; NSC-45517; CDAISMWEOUEBRE-GPIVLXJGSA-N; 488-54-0; CC-093; 40032-EP2298312A1; ZINC1530357; 13719-EP2308875A1; CHEBI:27987; AN-24133; epi-Inositol; (1r,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Pharmakon1600-01500352; CDAISMWEOUEBRE-GNIYUCBRSA-N; Tox21_111642; UNII-6R79WV4R10; 13719-EP2316836A1; SMR000857145; HMS2230N03; (1s,2s,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol; mesoinositol; NCGC00159409-04; CHEBI:27372; CJ-05199; SCHEMBL6378921; AK115152; (1/4) inverted exclamation markIC; SCHEMBL491333; myo-Inositol, Vetec(TM) reagent grade, 99%; 3635-EP2275412A1; ELND005; NCGC00169828-01; I0632; EINECS 207-681-5; 3635-EP2295437A1; SCHEMBL14542470; MolPort-003-848-190; Muco-Inositol; D0Y4UQ; Epi-inositol, 98%; 1,2,3,4,5,6/0-cyclohexanetetrol; Mesovit; D-chiro-Inositol, >=98.0% (HPLC); TRA-0204644; 36190-90-6; NSC 25142; cis-Inositol; (1R,2R,3S,4R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; SCHEMBL12377889; cis-1,2,3,5-trans-4,6-Cyclohexanehexol; i-Inositol; L-Inositol; CHEBI:10642; 12513-EP2305825A1; Chiro-inositol, (-)-; Inositol, muco-; Quercinitol; M94176HJ2F; HY-B1411; SCHEMBL12711208; SCHEMBL13580047; CDAISMWEOUEBRE-CDRYSYESSA-N; scyllo-Cyclohexanehexol; ZINC101185827; Allo-inositol; Tox21_111642_1; HMS3373E05; 1,3,5/4,6-Cyclohexanehexol; EINECS 209-000-7; KS-1284; W-203168; 13719-EP2280010A2; Phaseomannite; EPIINOSITOL; (+)-Epi-Inositol; NSC45517; Inositol (NF); 6643AB; (1R,2R,3S,4S,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; SCHEMBL4748543; AK307315; 13719-EP2269977A2; 488-58-4; UNII-M94176HJ2F component CDAISMWEOUEBRE-LKPKBOIGSA-N; cis-1,3,5-trans-4,6-Cyclohexanehexol; SCHEMBL13114128; SCHEMBL6468882; UNII-587A93P465; scyllo-Inositol, >=98%; SMR000857320; D-chiro Inositol; AZD 103; SCHEMBL188237; SCHEMBL12411898; bmse000113; epi-Inositol, >=98.0% (HPLC); MLS001335967; 19030-27-4; AK307406; INOSITOL (L); KBio2_007211; Cyclohexane-1,2,3,4,5,6-hexaol; 41546-34-3; (1S,4S)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; NSC8101; NSC-55551; 63GQX5QW03; (1R)-Cyclohexane-1r,2c,3t,4c,5t,6t-hexaol; myo -Inositol; ZINC306121118; D08DXZ; ST24049158; AX8234329; Inositol, epi-; TRA0065469; 551-72-4; 488-59-5; NSC55551; 1D7A27BF-6060-4FA9-AC46-3BD18DBA406E; 3635-EP2298312A1; Myoinosite; HMS2235M23; NSC-55552; Inositol [Nonspecific isomer]; A836375; SR-05000001655-5; myo-Inositol, SAJ special grade, >=99.0%; 13719-EP2298734A2; D-chiro-Inositol; HMS2235H05; AN-18118; (1S,2R,4R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; KBio3_001826; Inositol, meso-; ZINC103574467; AS-10616; CAS-87-89-8; Inositina; SCHEMBL959404; I0629; BG00909545; AmbotzGBB1246; EINECS 211-393-5; 1,3,5/2,4,6-cyclohexanehexol; EINECS 201-781-2; SCHEMBL5831; Meat sugar; neoinositol; 9O6Y5O4P9W; (-)-chiro-Inositol; 13719-EP2289891A2; AKOS015895894; 13719-EP2295437A1; (-)-Inositol; NSC55552; Cyclohexanehexol; Inosital (TN); Levoinositol; FT-0632208; BG01505583; cyclohexane-1R,2R,3S,4S,5R,6S-hexol; TL8004550; L-chiro-Inositol; Myo inositol; Spectrum5_000961; (1R,2S,3S,4R,5S,6r)-cyclohexane-1,2,3,4,5,6-hexol; myo-inositol; (1S,2R,4S)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; MFCD00272608; MLS001332377; D08079; SCHEMBL12371461; meso-Inositol; D-myo-Inositol; Cyclohexitol; ZINC100018867; 1,2,3,4/5,6-cyclohexanehexol; D-(+)-chiro-Inositol, 95%; (1R,2R,3S,4S,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; ACon1_002457; KBioGR_001885; NSC-8101; TR-019452; FT-0670357; AKOS015994742; ZINC100032893; NSC757076; CS-4782; allo-Inositol, 97%; AN-23658; Mesoinosit; KS-00000QA9; AKOS027320475; KBio2_004643; ZINC103574475; UNII-4L6452S749; SCHEMBL5969; ZINC100055570; 1,3,5/2,4,6-Hexahydroxycyclohexane; KS-000017FC; 3635-EP2298775A1; bmse000901; FCH1118762; NCGC00159409-03; R1Y9F3N15A; I14-101844; myo-Inositol, for microbiology, >=99.0%; I0633; Dambose; myo-Inositol, PharmaGrade, meets FCC testing specifications, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production.; FT-0693444; 1-L-chiro-Inositol; (1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexol; SR-05000001655-1; SCHEMBL188106; L-(-)-chiro-Inositol; L-myo-Inositol; 1,2,3,4,5,6-Cyclohexanehexaol; UNII-M94176HJ2F component CDAISMWEOUEBRE-SHFUYGGZSA-N; ZINC100513675; 173524-45-3; 643C129; NSC-55558; CCG-36096; Mouse antialopecia factor; FT-0632730; NSC55558; 8LQ63P85IC; I0628; MolPort-006-111-433; NCI60_041778; CDAISMWEOUEBRE-NIPYSYMMSA-N; KBioSS_002075; C00137; CBU; 220128F1-89BF-442D-AD6D-E6D1EA7BA625; UNII-R1Y9F3N15A; D0B1EY; 1,2,3,5-trans-4,6-Cyclohexanehexol, cis-; MolPort-003-933-930; 587A93P465; CHEBI:25492; NSC 404118; UNII-M94176HJ2F; MCULE-2727773046; J101.890F; HMS3369F20; SCHEMBL5832; UNII-8LQ63P85IC; 12513-EP2277881A1; UNII-4661D3JP8D; 53319-35-0; MLS001335968; 1,2,3,4,5,6-Cyclohexanehexol #; myo-Inositol, p.a., 98.0%; meso-(1/4) inverted exclamation mark (1/4); AC-11070; SCHEMBL959405; NCGC00178580-03; (1r,2R,3S,4s,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; I06-1350; 1L-Chiro-inositol; SCHEMBL1055883; Nucite; LS-2350; RP24128; 1,2,3,4,5/6-cyclohexanehexol; GTPL4648; Epitope ID:144993; SCHEMBL12735687; AKOS006332036; Inositol NF 12; MFCD00003863; AK546883; 1,2,4/3,5,6-cyclohexanehexol; 13719-EP2298775A1; EINECS 230-024-9; W-202862; (1R,2R,3S,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; NCGC00159409-02; 4661D3JP8D; 1L-myo-Inositol; Scyllo-inositol; C06152; Chiro-inositol, (+)-; Inositol, i-; CHEMBL1950780; 1,2,3,4,5,6-cyclohexanhexol; 1,2,3,4,5,6-cyclohexanehexol, (1alpha,2alpha,3alpha,4beta,5alpha,6beta); D-(+)-Chiro Inositol; SC-91157; KS-00001315; NP-010162; I14-47229; VC30505; 4CH-024633; KB-251247; MFCD00065455; (1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; CDAISMWEOUEBRE-UHFFFAOYSA-N; ZINC100024490; Inositol, allo-; AI3-16111; Ambap6917-35-7; HMS3369B06; 7B0CEF84-D9CE-4A88-AA7D-EC50C89387A5; 1,3,4,5,6-Cyclohexanehexol; inositol; W-202861; SCHEMBL187397; DSSTox_CID_3146; ZINC100035580; 40032-EP2311830A1; 12513-EP2298744A2; K-9876; INOSITOL, MESO; CHEBI:24848; bmse000103; TR-016439; SCHEMBL13207905; (+)-Inositol; CHEMBL122705;cocositol;D-myo-inositol C6H12O6 180.16 g/mol C1(C(C(C(C(C1O)O)O)O)O)O
TCMBANKIN058267 vitamin b NSC169454; SR-01000722017-4; Nicotinic acid, >=98%; [3H]nicotinic acid; Nicotinamide (JP15/INN); AC1Q73P3; C6H5NO2; 11054-EP2289510A1; NCGC00094734-02; AB00052050; HMS3655K08; Efacin; Nico-400; N1103; 11054-EP2298772A1; TR-032523; C00253; Nicosan 3; SPBio_000011; Nicotinic Acid [Matrix for MALDI-TOF/MS]; SPBio_002881; 5-22-02-00057 (Beilstein Handbook Reference); Niacinamide Astra Brand; Spectrum3_000515; ANW-75276; Bionic; 11054-EP2301923A1; SDCCGMLS-0066610.P001; Nicotinsaure [German]; Nicotinic acid, >=99.5% (HPLC); preventative factor; 28029-53-0 (cobalt(2+) salt); SR-01000722017-3; Acide nicotinique [INN-French]; 11054-EP2295409A1; NICO; InChI=1/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9; D00049; Jenapharm Brand of Niacinamide; Nicotinamide (TN); Niacin [USAN]; bmse000104; 1976-28-9 (aluminum salt); 11054-EP2311816A1; Apelagrin; AN-23622; KBio2_001543; ABT-919; Acido nicotinico; .beta.-Pyridinecarboxylic acid; Niaspan (TN); 11054-EP2270002A1; SR-01000722017-2; KB-33243; Pellagramin; NCGC00016268-02; DSSTox_CID_932; Merck Brand of Niacinamide; nicobid; beta-pyridinecarboxylic acid; BDBM23515; 3PyrCOOH; Nicotinic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, >=98%; Pellagra preventive factor; niacin; Prestwick0_000881; Nicotinic acid, Ph Eur; BPBio1_000730; Nicacid; UNII-2679MF687A; EBD2198325; NCGC00016268-08; 3-Carboxypyridine; ST097540; Z56755709; Davitamon PP; Nicotinamide (Niacinamide); Nicotinic acid, analytical standard; CPD000059024; 3-Pyridylcarboxylic acid; Pyridine-beta-carboxylic acid; KBioSS_001543; 11054-EP2305674A1; Nicotinic acid, for synthesis, 99%; Nicodon; Oprea1_514398; [5, 6-3H]-niacin; 636-79-3 (hydrochloride); Direktan; Niacin (Nicotinic Acid), Pharmaceutical Secondary Standard; Certified Reference Material; DB-007765; 11054-EP2298742A1; Nyclin; 11054-EP2316827A1; NSC-169454; 7069-06-9 (magnesium salt); 11054-EP2316826A1; Niacor; niacine; MLS000069603; AC-907/25014105; GTPL1594; Spectrum5_001287; RP00705; niacin potassium; BSPBio_002069; STR00112; IDI1_000695; LS-2334; AM81316; NAH; P.P. factor-pellagra preventive factor; AC-22484; Vitaplex N; Nicodan; 3789-96-6 (tartrate); 11054-EP2311829A1; AB1002056; Niacinamide Merck Brand; Spectrum4_000965; Pyridinecarboxylic acid, 3-; CCRIS 1902; 11054-EP2308838A1; SBI-0051456.P003; 11054-EP2280001A1; Nicotinic acid [INN]; PubChem2594; Nicovasen; 54-86-4 (hydrochloride salt); 11054-EP2274983A1; 11054-EP2308854A1; NCGC00016268-04; MCULE-3788394698; Nicagin; nicolar; NIASPAN TITRATION STARTER PACK; AB00052050-13; ST2413625; J-523605; 36321-41-2 (ammonium salt); Acido nicotinico [INN-Spanish]; Akotin; EINECS 200-441-0; SBB004279; 11054-EP2311830A1; Niacin, United States Pharmacopeia (USP) Reference Standard; Acidum nicotinicum; Nikasan; SR-01000722017; AK-46486; Enduracin; CS-1946; Nicotinic acid, certified reference material, TraceCERT(R); Induracin; Nico-Span; antipellagra vitamin; 3-pyridine carboxylic acid; Nicoside; Nicotinic acid, purum, >=99.0% (HPLC); CHEMBL573; Pyridylcarboxylic Acid; Tinic; 11054-EP2295424A1; EPA Pesticide Chemical Code 056701; Nicotine acid; Ncotnc acd; 11054-EP2305651A1; pellagra; Nicorol; 5-pyridinecarboxylic acid; NCGC00094734-01; 11054-EP2298776A1; 3-Picolinic acid; Niacin; Pellagra preventive factor; Pyridine-3-carboxylic acid; Vitamin B3; KBioGR_001309; 11054-EP2308848A1; KSC236Q9T; Nipellen; Niacin (USP); 3-pyridinecarboxylic acid; Vitamin B3 (Niacin); KBio2_006679; NCI60_001041; HMS2236A05; AB00052050_14; Nicotinic acid, matrix substance for MALDI-MS, >=99.5% (HPLC); HMS2097B04; Spectrum2_000006; 99148-57-9 (tosylate); SCHEMBL1433; BSPBio_000662; MolPort-000-142-273; KBio3_001569; 10361-13-4 (iron(2+) salt); Tox21_110337_1; F2191-0082; Acide nicotinique; Nicotinic acid, European Pharmacopoeia (EP) Reference Standard; 11054-EP2269990A1; 11054-EP2308858A1; M-5918; 11054-EP2275401A1; Nicotinic acid, plant cell culture tested; Nicotinic acid, SAJ special grade, >=99.5%; Niacinamide (TN); HMS3714B04; STK301803; Pelonin; Niconazid; Prestwick2_000881; Nicovasan; 11054-EP2270014A1; Niacinamide Pharmagenix Brand; Pharmakon1600-01500430; Pyridine-carboxylique-3 [French]; SK-Niacin; Prestwick1_000881; Nikazan; EC 200-441-0; PP Factor; AKOS000118980; HY-B0143; Tox21_110337; HMS3371E07; WLN: T6NJ CVQ; Nicotene; Nicotinic acid [INN:BAN]; CAS-59-67-6; 11054-EP2316458A1; Kyselina nikotinova [Czech]; P.P. factor; Pyridine-3-carboxylic acid; Niacin (nicotinic acid); Tox21_201420; L001199; NCGC00016268-09; nicocap; I02-0699; nicotinic acid; Niconat; ZINC1795; Niacin [USP]; Diacin; 11054-EP2272825A2; Kyselina nikotinova; FC1287; Nicotinic acid-d3(major); CHEBI:15940; 823-77-8 (calcium salt); Niacor (TN); DSSTox_RID_75875; NCGC00256537-01; Nicotamin; GTPL1588; 2679MF687A; ACMC-1AS6M; [3H]-Nicotinic acid; SPECTRUM1500430; Acidum nicotinicum [INN-Latin]; HMS1570B04; 11054-EP2301937A1; KBio1_000695; BP-21419; Niacinamide Jenapharm Brand; AJ-08093; Nicotinic acid, NIST(R) SRM(R) 148; niacin magnesium; Nicyl; S115; Tega-Span; 11054-EP2269610A2; KBio2_004111; AC1L1AD5; NCGC00016268-01; Niacinamide, Nicotinic acid amide, Nicotinamide; Opera_ID_1346; Nicotinic acid, 99% 250g; 3-Pyridyl carboxylic acid; Nicocidin; nicotinate; s1744; SR 4390; DTXSID1020932; Nicotinsaure; 16518-17-5 (potassium salt); Nicotinic acid, Vetec(TM) reagent grade, >=98%; 11054-EP2308839A1; Linic; BIDD:GT0644; NC00524; wampocap; NCGC00016268-03; Nicotinic acid, for inorganic trace analysis, >=99.999% (metals basis); AB00052050_15; Nicosyl; CCG-38340; D06NVJ; 11054-EP2301935A1; 11054-EP2308874A1; Nikotinsaeure; SC-05611; Pyridine-3-carbonic acid; Nicodelmine; 53890-72-5 (lithium salt); 11054-EP2311808A1; SMR000059024; Daskil; NSC 169454; MFCD00006391; PS-4255; HMS502C17; 11054-EP2272848A1; FT-0082580; Pyridine-.beta.-carboxylic acid; DivK1c_000695; 11054-EP2295406A1; Niacin-Vitamin B3; N0082; BRN 0109591; 3-Carboxylpyridine; 11054-EP2316828A1; Niac; NCGC00258971-01; 3-Picolinic acid; 11054-EP2292610A1; NINDS_000695; 11054-EP2292228A1; FT-0600004; Astra Brand of Niacinamide; Nicotinic Acid 1.0 mg/ml in Methanol; 11054-EP2272834A1; HMS3259K21; Niacin (TN); Nicotinic acid (JP17/INN); NSC-757241; Prestwick3_000881; Niaspan; Slo-niacin; SAM002554917; HMS2091H22; Pharmagenix Brand of Niacinamide; 59-67-6; NCGC00016268-05; Tox21_302904; Pellagrin; Caswell No. 598; 11054-EP2277848A1; 3DDB011E-F3A6-45B6-A2D2-77B2A6E8936E; 11054-EP2301929A1; 11054-EP2311817A1; Naotin; m-Pyridinecarboxylic acid; vitamin B3; HSDB 3134; Peviton; nicamin; Nicotinic acid (Vitamin B3) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Nicangin; Spectrum_001063; Pyridine-carboxylique-3; KB-259513; 11054-EP2298779A1; Nicocrisina; DB00627; 11054-EP2316825A1; AI3-18994; PVNIIMVLHYAWGP-UHFFFAOYSA-N; 11054-EP2316457A1; I14-92791; anti-Pellagra vitamin; 28029-54-1 (manganese(2+) salt); NSC757241; 123574-58-3; Nicotil; HMS1920P17; Nicotinipca; 3-Pyridinecarboxylicacid; 11054-EP2314588A1; Niconacid; NIO; Nicotinic acid, meets USP testing specifications; DSSTox_GSID_20932; Nicotinamide-carbonyl-14C C5H4NCOOH 123.11 g/mol C1=CC(=CN=C1)C(=O)O
TCMBANKIN058601 oxysophocarpine N1280; AC-7981; SCHEMBL15133349; 26904-64-3; N-Oxysophocarpine; n-oxysophocarpine; AKOS015965398; 2,3,6,7,7a,8,13,13a,13b,13c-Decahydro-1H,5H,10H-dipyrido[2,1-f:3,2,1-ij][1,6]naphthyridin-10-one 4-oxide #; QMGGMESMCJCABO-UHFFFAOYSA-N; Oxysophocarpine; Sophocarpine, N-oxide; 6-OXO-7,13-DIAZATETRACYCLO[7.7.1.0(2),?.0(1)(3),(1)?]HEPTADEC-4-EN-13-IUM-13-OLATE; AC1LDHOM; FT-0689395; sophocarpine n-oxide; N-oxysophocarpine; OXYSOPHOCARPINE C15H22N2O2 262.35 g/mol C1CC2CN3C(CC=CC3=O)C4C2[N+](C1)(CCC4)[O-]
TCMBANKIN059531 eucalyptol C10H18O 154.25 g/mol CC1(C2CCC(O1)(CC2)C)C
TCMBANKIN059820 atractylenolide iii; codonolactone C15H20O3 248.32 CC1=C2CC3C(=C)CCCC3(CC2(OC1=O)O)C
TCMBANKIN060947 Sanleng acid C18H34O5 330.46 CCCCCCCCC(C(C=CC(CCCCC(=O)O)O)O)O
TCMBANKIN061320 cryptopine C21H23NO5 369.41 CN1CCC2=CC(=C(C=C2C(=O)CC3=C(C1)C4=C(C=C3)OCO4)OC)OC
TCMBANKIN061324 d-reticuline (S)-(+)-reticuline; (1S)-1-[(3-hydroxy-4-methoxy-phenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; CHEBI:16718; 485-19-8; (1S)-1-(3-hydroxy-4-methoxy-benzyl)-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; (+)-Reticuline; (1S)-1-(3-hydroxy-4-methoxybenzyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; (1S)-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; C02105;CHEBI:17428; AC1L99KR; (R)-(-)-reticuline; (1R)-1,2,3,4-Tetrahydro-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-7-isoquinolinol; AK552295; (1R)-1-(3-hydroxy-4-methoxybenzyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; C05178; FT-0699770; MFCD28556897; ZINC901258; DTXSID80331501; L-Reticuline; CHEMBL401501; AKOS030242061; (1R)-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; (R)-Reticuline; (-)-reticuline; SCHEMBL9587509; NCGC00247617-01; 3968-19-2; (R)-Reticuline (>80% ee); CTK1C2641; (S)-Reticuline;reticuline;reticulin C19H23NO4 329.4 g/mol CN1CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)O)O)OC
TCMBANKIN061351 Insularine insularine; UNII-60I96OKL0W; O-Methylinsulanoline; 60I96OKL0W; 549-07-5; 6,9-(Epoxymethano)-8,11:20,23-dietheno-1H,12H-(1,10)dioxacyclooctadecino(2,3,4-ij:11,12,13-i'j')diisoquinoline, 2,3,12a,13,14,15,24,24a-octahydro-5,17,18-trimethoxy-1,13-dimethyl-, (12aR,24aR)-; Insularine [MI] C38H40N2O6 620.7 g/mol CN1CCC2=CC(=C3C4=C2C1CC5=CC=C(C=C5)OC6=C7C(CC8=CC(=C(O4)C=C8)CO3)N(CCC7=CC(=C6OC)OC)C)OC
TCMBANKIN061352 longatin (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one; NSC121869; SMR000059119; (S,R)-Noscapine; C09592; STK054401; BSPBio_000346; 128-62-1; AIDS011873; (3S)-3-[(5R)-6-methyl-4-(methyloxy)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6,7-bis(methyloxy)-2-benzofuran-1(3H)-one; Lopac0_000840; Tocris-1697; Noscapine (TN); alpha-Narcotine; .beta.-Narcotine; alpha-narcotine; EINECS 204-899-2; Noscapine [BAN:INN:JAN]; Coscopin (VAN); L-alpha-Narcotine; 4-27-00-06838 (Beilstein Handbook Reference); 1368-39-4; Lopac-N-9007; 1(3H)-Isobenzofuranone,6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)-isoquinolin-5-yl),(S-(R*,S*))-; L-alpha-Noscapine; CAS-128-62-1; BRN 0099933; BSPBio_002113; SDCCGMLS-0066644.P001; 1(3H)-Isobenzofuranone,6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-,(S-(R*,S*))-; HSDB 3372; KBio2_004117; TNP00110; SPBio_001053; (3R)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-isobenzofuran-1-one; NCGC00017174-02; 567-86-2; KBio2_006685; Spectrum5_001276; (-)-alpha-Norcotine; NCGC00017174-01; KBioGR_000872; Spectrum2_000987; (3R)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one; Noscapinum [INN-Latin]; NCGC00015757-01; Spectrum_001069; KBio3_001613; ST055757; (-)-Narcotine; Spectrum3_000527; 8-Methoxyhydrastin; 5-(6,7-Dimethoxyphthalidyl)-5,6,7,8-tetrahydro-4-methoxy-8-methyl-1,3-dioxolo(4,5-g)isoquinoline; L-alpha-2-Methyl-8-methoxy-6,7-methylenedioxy-1-(6,7-dimethoxy-3-phthalidyl)-1,2,3,4-tetrahydroisoquinaline; TNP00034; KBio2_001549; Spectrum4_000456; Longactin; 8057-19-0; Noscapina [INN-Spanish]; KBioSS_001549; (-)-3-(2-Methyl-6,7-methylendioxy-8-methoxy-1-isochinolyl)-6,7-dimethoxyphthalid; NCGC00016388-01; Narcotine (8CI); 8055-18-3; NCGC00023230-02; AIDS-011873; D01036; CBMicro_048259; SPBio_002565; BIM-0048054.P001; NCI60_004322; Prestwick1_000563; Prestwick3_000563; (-)-.alpha.-Narcotine; Prestwick_959; (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-isobenzofuran-1-one; MLS000069475; 363960_ALDRICH; BPBio1_000382; Coscopin; Methoxyhydrastine; Prestwick0_000563; Prestwick2_000563; Noscapine (JP15/USP/INN); AC1NSW29; 5-[(1S)-4,5-dimethoxy-3-methylidene-1H-2-benzofuran-1-yl]-4-methoxy-6,9-dimethyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinoline; narcotine; Noscapine; gnoscopine; Noskapin; α-narcotine C22H23NO7 413.42 g/mol CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3
TCMBANKIN061354 Fumarine C05189; TNP00339; 7-methyl-2,3:9,10-bis[methylenebis(oxy)]-7,13a-secoberbin-13a-one; ST036759; Bis[1,3]benzodioxolo[4,5-c:5',6'-g]azecin-13(5H)-one, 4,6,7,14-tetrahydro-5-methyl-; Bis(1,3)benzodioxolo(4,5-c:5',6'-g)azecin-13(5H)-one, 4,6,7,14-tetrahydro-5-methyl-; HSCI1_000268; EINECS 204-999-6; AIDS-040935; Corydinine; 4,6,7,14-Tetrahydro-5-methyl-bis(1,3)benzodioxolo(4,5-c-5',6'-g)azecin-13(5H)-one; Oprea1_722246; NCGC00142402-01; Biflorine; Macleyine; 130-86-9; NCGC00017389-01; 7-methyl-6,8,9,16-tetrahydrobis[1,3]benzodioxolo[4,5-c:5',6'-g]azecin-15(7H)-one; 7,13a-Secoberbin-13a-one, 7-methyl-2,3:9,10-bis(methylenedioxy)-; Alk-3; 6164-47-2 (HCL); Oprea1_718853; AIDS040935; 7-Methyl-2,3:9,10-bis(methylenedioxy)-7,13a-secoberbin-13a-one; HSDB 3527; CHEBI:16415; AI3-62909; ACon1_001550; DTXSID00178935; Bis(1,3)benzodioxolo(5,6-c:5',6'-g)azecin-14(6H)-one, 5,7,8,15-tetrahydro-6-methyl-; Bis[1,3]benzodioxolo[5,6-c:5',6'-g]azecin-14(6H)-one,5,7,8,15-tetrahydro-6-methyl-; AC1L4H3I; CHEMBL486179; 14-METHYL-7,9,20,22-TETRAOXA-14-AZAPENTACYCLO[15.7.0.0?,(1)(2).0?,(1)?.0(1)?,(2)(3)]TETRACOSA-1(24),4,6(10),11,17,19(23)-HEXAEN-2-ONE; CTK4F3162; MCULE-2865552640; BDBM50377937; 24240-05-9; AC1Q6P91; NCGC00385257-01_C20H19NO5_1,3-Benzodioxolo[5,6-c][1,3]benzodioxolo[5,6-g]azecin-14(6H)-one, 5,7,8,15-tetrahydro-6-methyl-; C20H19NO5; protopine ; Pseudoprotopine; MolPort-028-610-216; 6-methyl-5,7,8,15-tetrahydrobis[1,3]benzodioxolo[5,6-c:5',6'-g]azecin-14(6h)-one; 7,13a-Secoberbin-13a-one, 7-methyl-2,3:10,11-bis(methylenedioxy)-; ZINC31502517; protopine C20H19NO5 353.37 CN1CCC2=CC3=C(C=C2C(=O)CC4=C(C1)C5=C(C=C4)OCO5)OCO3
   植物对应的疾病
疾病ID 病名 疾病类型 MeSH 参考文献
   植物对应的靶点
靶点ID 基因名 基因别名 描述 染色体位置 Map_Location 基因类型

Home | Browse | Search | Predict | Data | Contact | Help

Copyright © KUST | 滇ICP备16009434号-1 | Dai SX Lab